Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TACR3 | P29371 | 2/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20312651 | 0.93 | ALDH1A1 (0.47) | NSD2KMT2AALDH1A1HTTMEN1 | |
| SCHEMBL22344174 | 0.91 | NSD2 (0.42) | NSD2KMT2AALDH1A1HTTMEN1 | |
| SCHEMBL20312544 | 0.90 | KMT2A (0.50) | KMT2AALDH1A1HTTMEN1KDM1A | |
| SCHEMBL22344170 | 0.89 | ALDH1A1 (0.44) | NSD2KMT2AALDH1A1HTTMEN1 | |
| SCHEMBL20303043 | 0.89 | NSD2 (0.40) | NSD2KMT2AALDH1A1HTTMEN1 | |
| SCHEMBL20302759 | 0.88 | ALDH1A1 (0.42) | KMT2AALDH1A1HTTMEN1HSD17B1 | |
| SCHEMBL20312631 | 0.86 | NSD2 (0.46) | NSD2KMT2AALDH1A1HTTROCK2 | |
| SCHEMBL22344147 | 0.86 | ALDH1A1 (0.41) | KMT2AALDH1A1HTTMEN1TACR3 | |
| SCHEMBL20302726 | 0.85 | ALDH1A1 (0.42) | KMT2AALDH1A1HTTMEN1 | |
| SCHEMBL20312681 | 0.84 | ALDH1A1 (0.42) | KMT2AALDH1A1HTTMEN1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261421-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| WO-2018118827-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261421-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | PREP, SERPINB1, PEPD | NSD2 1226/4885KMT2A 2246/4885ALDH1A1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.